Literature DB >> 15541764

Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.

Charmian A Quigley1, Jiann-an Tan, Bin He, Zhong-xun Zhou, Farida Mebarki, Yves Morel, Maguelone G Forest, Pierre Chatelain, E Martin Ritzén, Frank S French, Elizabeth M Wilson.   

Abstract

Partial androgen insensitivity with sex phenotype variation in two unrelated families was associated with missense mutations in the androgen receptor (AR) gene that disrupted the AR NH(2)-terminal/carboxy terminal interaction. Each mutation caused a single amino acid change within the region of the ligand-binding domain that forms activation function 2 (AF2). In one family, the mutation I737T was in alpha helix 4 and in the other F725L was between helices 3 and 4. Neither mutation altered androgen binding as determined by assays of mutant AR in the patient's cultured genital skin fibroblasts or of recombinant mutant receptors transfected into COS cells. In transient cotransfection assays in CV1 cells, transactivation with the AR mutants at low concentrations of DHT was reduced several fold compared with wild-type AR but increased at higher concentrations. Defects in NH(2)-terminal/carboxy terminal interactions were identified in mammalian two hybrid assays. In similar assays, there was reduced binding of the p160 coactivators TIF2/SRC2 and SRC1 to the mutant AR ligand binding domains (LBD). In the family with AR I737T, sex phenotype varied from severely defective masculinization in the proband to a maternal great uncle whose only manifestation of AIS was severe gynecomastia. He was fertile and passed the mutation to two daughters. The proband of the F725L family was also incompletely masculinized but was raised as a male while his half-sibling by a different father was affected more severely and reared as a female. These studies indicate that the function of an AR AF2 mutant in male development can vary greatly depending on the genetic background.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541764     DOI: 10.1016/j.mad.2004.08.007

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  15 in total

1.  Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Authors:  William H Lagarde; Amanda J Blackwelder; John T Minges; Andrew T Hnat; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

2.  Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor.

Authors:  Qiang Liu; Shifeng Su; Amanda J Blackwelder; John T Minges; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

3.  Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology.

Authors:  Azriel Schmidt; Donald B Kimmel; Chang Bai; Angela Scafonas; Sujane Rutledge; Robert L Vogel; Sheila McElwee-Witmer; Fang Chen; Pascale V Nantermet; Viera Kasparcova; Chih-Tai Leu; Hai-Zhuan Zhang; Mark E Duggan; Michael A Gentile; Paul Hodor; Brenda Pennypacker; Patricia Masarachia; Evan E Opas; Sharon A Adamski; Tara E Cusick; Jiabing Wang; Helen J Mitchell; Yuntae Kim; Thomayant Prueksaritanont; James J Perkins; Robert S Meissner; George D Hartman; Leonard P Freedman; Shun-ichi Harada; William J Ray
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

Review 4.  Structural features discriminate androgen receptor N/C terminal and coactivator interactions.

Authors:  Emily B Askew; John T Minges; Andrew T Hnat; Elizabeth M Wilson
Journal:  Mol Cell Endocrinol       Date:  2011-06-01       Impact factor: 4.102

5.  Long-term biochemical evaluation of the androgen receptor pathway in males with disorders of sex development.

Authors:  C Schwentner; J Czyz; J Seibold; T Todenhoefer; S H Alloussi; H Klocker; G Gakis; A Stenzl; M Baka-Ostrowska; C Radmayr
Journal:  World J Urol       Date:  2010-12-15       Impact factor: 4.226

6.  Analysis of interdomain interactions of the androgen receptor.

Authors:  Elizabeth M Wilson
Journal:  Methods Mol Biol       Date:  2011

7.  Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands.

Authors:  Azriel Schmidt; Shun-Ichi Harada; Donald B Kimmel; Chang Bai; Fang Chen; Su Jane Rutledge; Robert L Vogel; Angela Scafonas; Michael A Gentile; Pascale V Nantermet; Sheila McElwee-Witmer; Brenda Pennypacker; Patricia Masarachia; Soumya P Sahoo; Yuntae Kim; Robert S Meissner; George D Hartman; Mark E Duggan; Gideon A Rodan; Dwight A Towler; William J Ray
Journal:  J Biol Chem       Date:  2009-10-21       Impact factor: 5.157

8.  Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor.

Authors:  Suxia Bai; Elizabeth M Wilson
Journal:  Mol Cell Biol       Date:  2008-01-22       Impact factor: 4.272

9.  Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.

Authors:  Emily B Askew; Robert T Gampe; Thomas B Stanley; Jonathan L Faggart; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2007-06-25       Impact factor: 5.157

10.  Mechanism of androgen receptor corepression by CKβBP2/CRIF1, a multifunctional transcription factor coregulator expressed in prostate cancer.

Authors:  Jiann-An Tan; Suxia Bai; Gail Grossman; Mark A Titus; O Harris Ford; Elena A Pop; Gary J Smith; James L Mohler; Elizabeth M Wilson; Frank S French
Journal:  Mol Cell Endocrinol       Date:  2013-10-05       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.